Digestive Health Outcomes Registry for patients with GI disease

The American Gastroenterological Association (AGA), the leading association representing clinicians and researchers who specialize in the digestive tract, and MedAssurant, Inc., a leading provider of data-driven healthcare solutions, announced today the collaborative initiative to develop a set of registries to assist physicians, payors, policy makers, and other healthcare stakeholders in the study and improvement of clinical and quality outcomes, care management, and cost effectiveness of care delivered to Americans with gastrointestinal disease.

“As part of our commitment to advancing the science and practice of gastroenterology, AGA is taking the lead in collecting, aggregating, and analyzing data on gastrointestinal diseases. The AGA Digestive Health Outcomes Registry is a groundbreaking project that will support clinicians in advancing the quality and effectiveness of care, researchers in investigating GI disease, and policy-makers in making decisions based on sound evidence,” said Gail A. Hecht, MD, MS, AGAF, president of the AGA Institute, which administers practice, research and education programs of the organization. “The AGA is committed to responding to this need, and doing so quickly and effectively. MedAssurant’s experience with the aggregation and analysis of data, and its extensive infrastructure and datasets, will make it possible for AGA to achieve this quickly, and to provide both our members and the broader healthcare community with a set of tremendously valuable registry-based tools. We look forward to partnering with stakeholders on this important initiative.”

According to the National Institutes of Health, there are between 60 and 70 million Americans afflicted with digestive diseases. The cost of this burden exceeds $140 billion per year in both direct and indirect expenses. MedAssurant maintains a nationwide clinical and technology infrastructure which enables efficient, large scale, healthcare data aggregation throughout the United States, sophisticated clinical data management platforms, and advanced healthcare data analytic prowess. These toolsets, combined with MedAssurant’s MORE Registry™, a powerful clinical dataset designed around medical outcomes research for effectiveness and economics, enables rapid achievement of advanced insights for healthcare advancement and improvement.

“There is a growing call for evidence-based decision-making at all levels of health care,” said Cary Sennett, MD, PhD, Chief Medical Officer at MedAssurant and Vice-Chair of the AMA Physicians Consortium for Performance Improvement. “Physicians are seeking the benefit of evaluating their own results, researchers desire better tools to guide advancement and safety surveillance, and policy-makers need to be able to compare the effectiveness of alternative treatments. Bringing together the unmatched clinical expertise of AGA and the data collection, aggregation, and analytics capabilities of MedAssurant creates a powerful combination that promises to accelerate efforts to gain improved insights into the quality and cost-effectiveness of GI care.”

The AGA-MedAssurant initiative will launch a series of registries to address high cost and high variation aspects of care for patients with GI disease, including colonoscopy/colorectal cancer screening, inflammatory bowel disease, GERD, viral hepatitis, and obesity, as well as other conditions and procedures. Areas of interest have been expressed by industry-leading gastroenterological stakeholders and these interests will be used to shape the initiative.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals AI's potential and pitfalls in medical diagnosis